SCHEDULE 13G: Point72 Discloses 5.9% Passive Stake in Immunome Inc.

Point72 Asset Management, L.P., along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has disclosed a passive beneficial ownership of 5.9% in Immunome Inc., totaling 4,887,110 shares.

Summary

• Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly filed a Schedule 13G, indicating beneficial ownership in Immunome Inc.
• The reporting persons collectively own 4,887,110 shares of Immunome Inc.'s common stock.
• This ownership represents 5.9% of the total outstanding shares of Immunome Inc.
• The shares are held by Point72 Associates, an investment fund managed by Point72 Asset Management, L.P.
• Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management, L.P., and Steven A. Cohen controls both entities.
• The beneficial ownership is primarily characterized by shared voting and shared dispositive power over the shares.
• The percentage of ownership is based on 82,680,126 shares outstanding as of January 31, 2025, following Immunome Inc.'s underwritten public offering and the full exercise of the underwriter's option to purchase additional shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. The presence of a significant institutional investor can be seen as a positive signal, but the filing itself is purely informational.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding future financial performance or strategic direction.

Industry Context

This filing indicates a significant passive investment by a prominent hedge fund in a publicly traded biotechnology company. Such disclosures are common and provide transparency regarding institutional ownership, which can be viewed as a vote of confidence in the company's long-term prospects by a sophisticated investor.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception and liquidity.
• Investment Professionals: Offers insight into the portfolio holdings and investment strategies of Point72 Asset Management.

Key Dates

Keywords

Immunome Inc., Point72 Asset Management, Steven A. Cohen, Schedule 13G, beneficial ownership, common stock, investment fund, passive stake, biotechnology